Voya Investment Management LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 200.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 773,639 shares of the medical research company’s stock after acquiring an additional 516,007 shares during the quarter. Voya Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $522,246,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Corient Private Wealth LP acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $1,974,561,000. Bank of America Corp DE purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after purchasing an additional 22,827 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have commented on the stock. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Jefferies Financial Group reissued a “buy” rating and set a $630.00 price target (up from $585.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $650.00 to $780.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $690.00 to $760.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $683.64.
View Our Latest Stock Analysis on TMO
Insider Activity
In other news, CEO Marc Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 2,831 shares of the stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total transaction of $1,999,959.95. Following the transaction, the vice president directly owned 11,560 shares of the company’s stock, valued at $8,166,562. This represents a 19.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 13,106 shares of company stock worth $8,465,099. Insiders own 0.33% of the company’s stock.
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO opened at $686.70 on Wednesday. The stock has a fifty day moving average price of $674.07 and a 200 day moving average price of $557.70. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $727.56. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market cap of $254.43 billion, a PE ratio of 36.22, a P/E/G ratio of 2.82 and a beta of 0.84.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $5.79 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.92%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
